Text Size

Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation (ACT 4)

This study has been completed.
Sponsor:
Collaborator:
Cardiome Pharma
Information provided by:
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT00281554
First received: January 24, 2006
Last updated: April 1, 2008
Last verified: April 2008
History of Changes
  Purpose

This study is designed to determine the safety of RSD1235 in patients with atrial fibrillation.


Condition Intervention Phase
Atrial Fibrillation
 Drug: RSD1235
 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 3, Multi-Center, Open Label, Safety Study of RSD1235 in Subjects With Atrial Fibrillation

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Rate of conversion of atrial fibrillation to sinus rhythm for a minimum of 1 minute [ Time Frame: Infusion plus 1.5 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evaluate safety [ Time Frame: End of study ] [ Designated as safety issue: No ]

Enrollment: 254
Study Start Date: October 2005
Study Completion Date: January 2007
Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: RSD1235
IV
Other Names:
  • vernakalant
  • Kynapid

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject must have symptomatic AF
  • Subject must have adequate anticoagulant therapy

Exclusion Criteria:

  • Subject may not have Class IV congestive heart failure.
  • Subject may not have uncorrected electrolyte imbalance.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00281554

  Show 40 Study Locations
Sponsors and Collaborators
Astellas Pharma Inc
Cardiome Pharma
Investigators
Study Director: Use Central Contact Astellas Pharma US, Inc.
  More Information

No publications provided by Astellas Pharma Inc

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Sr Manager Clinical Trial Registry, Astellas Pharma US, Inc.
ClinicalTrials.gov Identifier: NCT00281554     History of Changes
Other Study ID Numbers: 05-7-012
Study First Received: January 24, 2006
Last Updated: April 1, 2008
Health Authority: United States: Food and Drug Administration
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Canada: Health Canada
Sweden: Medical Products Agency
Denmark: Danish Medicines Agency
South Africa: Medicines Control Council

Keywords provided by Astellas Pharma Inc:
Investigational Therapies
Atrial Fibrillation
Treatment Efficacy
 Treatment Effectiveness
Safety
RSD1235

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on May 23, 2013